Long-term oncological outcome after post-chemotherapy retroperitoneal lymph node dissection in men with metastatic nonseminomatous germ cell tumour

BJU International

Volumn 106, Issue 6, 2010, Pages 779-785

  Fléchon, Aude ^a   Tavernier, Emmanuelle ^a   Boyle, Helen ^a   Meeus, Pierre ^a   Rivoire, Michel ^a   Droz, Jean Pierre ^a  

^a CENTRE LÉON BÉRARD   (France)

Author keywords

chemotherapy; RPLND; surgery; testis cancer

Indexed keywords

BLEOMYCIN; CARBOPLATIN; CISPLATIN; ETOPOSIDE; ANTINEOPLASTIC AGENT;

ABDOMINAL BLEEDING; ADOLESCENT; ADULT; AGED; ARTICLE; BLEEDING; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER RELAPSE; CANCER SURGERY; CHYLOTHORAX; CHYLOUS ASCITES; DEEP VEIN THROMBOSIS; FOLLOW UP; GERM CELL TUMOR; HUMAN; INTESTINE OBSTRUCTION; LEG ISCHEMIA; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; LYMPHOCELE; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RENAL ARTERY THROMBOSIS; RETROSPECTIVE STUDY; TESTIS TUMOR; DISEASE FREE SURVIVAL; LYMPH NODE; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; NEOPLASMS, GERM CELL AND EMBRYONAL; ORCHIECTOMY; PATHOLOGY; PROCEDURES; PROGNOSIS; RETROPERITONEAL NEOPLASMS; RETROPERITONEUM; SECONDARY; STANDARDS; TESTICULAR NEOPLASMS; TREATMENT OUTCOME; TUMOR RECURRENCE; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC AGENTS; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; HUMANS; LYMPH NODE EXCISION; LYMPH NODES; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASMS, GERM CELL AND EMBRYONAL; ORCHIECTOMY; PROGNOSIS; RETROPERITONEAL NEOPLASMS; RETROPERITONEAL SPACE; RETROSPECTIVE STUDIES; TESTICULAR NEOPLASMS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 77956218270     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2009.09175.x     Document Type: Article

References (38)

1. Williams SD, Birch R, Einhorn LH et al. Treatment of disseminated germ-cell tumours with cisplatin, bleomycin and either vinblastine or etoposide. N Engl J Med 1987 316 : 1435 1440
2. Donohue JP, Zachary JM, Maynard BR. Distribution of nodal metastases in nonseminomatous testis cancer. J Urol 1982 128 : 315 320
3. Donohue JP. Evolution of retroperitoneal lymphadenectomy (RPLND) in the management of non-seminomatous testicular cancer (NSGCT). Urol Oncol 2003 21 : 129 132
4. Donohue JP, Thomhill JA, Foster RS et al. Retroperitoneal lyphadenectomy for clinical stage A testis cancer (1965-89): modifications of technique and impact on ejaculation. J Urol 1993 149 : 237 243
5. Wood DP Jr., Herr HW, Heller G et al. Distribution of retroperitoneal metastases after chemotherapy in patients with nonseminomatous germ cell tumors. J Urol 1992 148 : 1812 1815
6. Aprikian AG, Herr HW, Bajorin DF et al. Resection of post-chemotherapy residual masses and limited retroperitoneal lymphadenectomy in patients with metastatic testicular nonseminomatous germ cell tumors. Cancer 1994 74 : 1329 1334
7. Whitmore WF Jr. Surgical treatment of adult germinal testis tumors. Semin Oncol 1979 6 : 55 68
8. Sheinfeld J, Bajorin D. Management of the post-chemotherapy residual mass. Urol Clin North Am 1993 20 : 133 143
9. Toner GC, Panicek DM, Heelan RT et al. Adjunctive surgery after chemotherapy for nonseminomatous germ cell tumors: recommendations for patient selection. J Clin Oncol 1990 8 : 1683 1694
10. Einhorn EH. Testicular cancer: an oncological success story. Clin Cancer Res 1997 3 : 2630 2632
11. Bosl GJ, Motzer RJ. Testicular germ-cell cancer. N Engl J Med 1997 24 : 242 253
12. Fléchon A, Rivoire M, Droz JP. Management of advanced germ-cell tumors of the testis. Nat Clin Pract Urol 2008 5 : 262 276
13. International Germ Cell Consensus Classification: a prognostic factor-based staging system for metastatic germ cell cancers. International Germ Cell Cancer Collaborative Group. J Clin Oncol 1997 15 : 594 603
14. Steyerberg EW, Keizer HJ, Fossa SD et al. Prediction of residual retroperitoneal mass histology after chemotherapy for metastatic nonseminomatous germ cell tumor: multivariate analysis of individual patient data from six study groups. J Clin Oncol 1995 13 : 1177 1187
15. Kesler KA, Wilson JL, Cosgrove JA et al. Surgical salvage therapy for malignant intrathoracic metastases from nonseminomatous germ cell cancer of testicular origin: analysis of a single-institution experience. J Thorac Cardiovasc Surg 2005 130 : 408 415
16. Rivoire M, Elias D, De Cian F et al. Multimodality treatment of patients with liver metastases from germ cell tumors: the role of surgery. Cancer 2001 92 : 578 578
17. Goulet RJ Jr., Hardacre JM, Einhorn LH et al. Hepatic resection for disseminated germ cell carcinoma. Ann Surg 1990 212 : 290 293
18. Steyerberg EW, Keizer HJ, Habbema JD. Prediction models for the histology of residual masses after chemotherapy for metastatic testicular cancer. ReHiT Study Group. Int J Cancer 1999 83 : 856 859
19. Krege S, Beyer J, Souchon R et al. European consensus conference on diagnosis and treatment of germ cell cancer: a report of the second meeting of the European Germ Cell Cancer Consensus Group (EGCCCG): part II. Eur Urol 2008 53 : 497 513
20. NCCN. Clinical Guideline Practice in Oncology Testicular Cancer VI, 2010 : 1 - 30. Available at: http://wwwnccnorg/professionals/physician-gls/f- guidelinesasp. Accessed 28 August 2009
21. Albers P, Albrecht W, Algaba F et al. Guidelines on testicular cancer. Eur Urol 2005 48 : 885 894
22. Skinner DG, Leadbetter WF. The surgical management of testis tumors. J Urol 1971 106 : 84 93
23. Skinner DG. Considerations for management of large retroperitoneal tumors: use of the modified thoracoabdominal approach. J Urol 1977 117 : 605 609
24. Richie JP, Garnick MB. Changing concepts in the treatment of nonseminomatous germ cell tumors of the testis. J Urol 1984 131 : 1089 1092
25. Williams SD, Stablein DM, Einhorn LH et al. Immediate adjuvant chemotherapy versus observation with treatment at relapse in pathological stage II testicular cancer. N Engl J Med 1987 317 : 1433 1438
26. Coogan CL, Hejase MJ, Wahle GR et al. Nerve sparing post-chemotherapy retroperitoneal lymph node dissection for advanced testicular cancer. J Urol 1996 156 : 1656 1658
27. Donohue JP. Nerve-sparing retroperitoneal lymphadenectomy for testis cancer. Evolution of surgical templates for low-stage disease. Eur Urol 1993 23 (Suppl 44 6
28. Sheinfeld J, Bajorin D. Management of the post-chemotherapy residual mass. Urol Clin North Am 1993 20 : 133 143
29. Beck SD, Foster RS, Bihrle R et al. Is full bilateral retroperitoneal lymph node dissection always necessary for post-chemotherapy residual tumor? Cancer 2007 110 : 1235 1240
30. Foster RS, Donohue JP. Nerve-sparing retroperitoneal lymphadenectomy. Urol Clin North Am 1993 20 : 117 125
31. Herr HW. Does necrosis on frozen-section analysis of a mass after chemotherapy justify a limited retroperitoneal resection in patients with advanced testis cancer? Br J Urol 1997 80 : 653 657
32. Carver BS, Shayegan B, Eggener S et al. Incidence of metastatic nonseminomatous germ cell tumor outside the boundaries of a modified post-chemotherapy retroperitoneal lymph node dissection. J Clin Oncol 2007 25 : 4365 4369
33. Heidenreich A, Pfister D, Witthuhn R, Thüer D, Albers P. Post-chemotherapy retroperitoneal lymph node dissection in advanced testicular cancer: radical or modified template resection. Eur Urol 2008 55 : 217 226
34. Heidenreich A, Thüer D, Polyakov S. Post-chemotherapy retroperitoneal lymph node dissection in advanced germ cell tumours of the testis. Eur Urol 2008 53 : 260 272
35. Steiner H, Peschel R, Bartsch G. Retroperitoneal lymph node dissection after chemotherapy for germ cell tumours: is a full bilateral template always necessary? BJU Int 2008 102 : 310 314
36. Collette L, Sylvester RJ, Stenning SP et al. For the European Organization for Research and Treatment of Cancer Genito-Urinary Tract Cancer Collaborative Group and the Medical Research Council Testicular Cancer Working Party. Impact of the treating institution on survival of patients with 'poor-prognosis' metastatic nonseminoma. J Natl Cancer Inst 1997 91 : 839 846
37. Simunovic M, Baxter NN. Lymph node counts in colon cancer surgery: lessons for users of quality indicators. JAMA 2007 298 : 2194 2195
38. Fizazi K, Tjulandin S, Salvioni R et al. Viable malignant cells after primary chemotherapy for disseminated nonseminomatous germ cell tumors: prognostic group. J Clin Oncol 2001 19 : 2647 2657